PMCBHealthcare · BiotechnologyPMCB Stock Forecast: PharmaCyte Biotech, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 14 Sept 2026 — in the lower half.
PMCB stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores PharmaCyte Biotech, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (97): Smaller than most of the companies we track.
Value (6): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
PMCB stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on PMCB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 Nov 2021 | HC Wainwright & Co. | Initiates | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PMCB appears on the weeks it earns a place.
PMCB vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 15 Sept 2026, PharmaCyte Biotech, Inc. returned −62.9% against +15.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
PMCB analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
PharmaCyte Biotech, Inc. (PMCB) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 14.0×
- Price / sales
- —
- Price / book
- 0.1×
- EV / EBITDA
- −3.9×
Cheaper than 48% of US stocks
Cheaper than 90% of US stocks
Cheaper than 77% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 32% of US stocks
Higher than 30% of US stocks
- Return on equity
- −44.7%
- Return on assets
- −6.5%
- Dividend yield
- —
Higher than 23% of US stocks
Higher than 30% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
PharmaCyte Biotech, Inc. (PMCB) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
PharmaCyte Biotech, Inc. has a market value of $4.2M and an enterprise value of −$31.6M.
Revenue in the twelve months to 30 Apr 2026: $0.0.
Net income over the same four quarters: −$19.4M.
Free cash flow in the twelve months to 30 Apr 2026: −$5.2M.
PharmaCyte Biotech, Inc. spent $402K on share buybacks in the twelve months to 30 Apr 2026.
Trailing P/E: 14.0×; forward P/E: −1.0× — the forward figure prices analyst consensus estimates, not reported earnings.
PharmaCyte Biotech, Inc. employs 2 people.
Data provided by Twelve Data
PMCB vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own PharmaCyte Biotech, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about PMCB stock
How does Ticker Nerd's model rank PMCB?
As at 14 Sept 2026, PharmaCyte Biotech, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).
What is the PMCB stock forecast for 2030?
No analyst covering PharmaCyte Biotech, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PMCB are extrapolating price history, which says nothing about the business.
How has PMCB stock performed over the past year?
PharmaCyte Biotech, Inc. returned -62.9% over the 12 months to 15 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
What does PharmaCyte Biotech, Inc. do?
PharmaCyte Biotech, Inc. is a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes.
About PharmaCyte Biotech, Inc.
PharmaCyte Biotech, Inc. is a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes. Its core platform is Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology designed to support therapies for difficult-to-treat conditions, including inoperable pancreatic cancer and other solid tumors. The company’s work centers on applying this platform to create treatment candidates that protect and deliver living cells in a controlled way. PharmaCyte Biotech is also active in related areas such as malignant ascites, reflecting a broader focus on oncology and metabolic disease applications. Headquartered in Las Vegas, Nevada, PharmaCyte Biotech operates as a research-driven company in the health technology sector, with its current business concentrated on advancing product development and commercialization efforts in specialized cellular medicine.
CEO Mr. Joshua N. Silverman · 2 employees · United States · https://pharmacyte.com